1-4 of 4
Roy Beveridge, MD
Close
Sort by
Journal Articles

Economic Impact of Disease Progression In Follicular Non-Hodgkin's Lymphoma.

Sacha-Satram Hoang, PhD, Stephen Gruschkus, PhD, Joseph Darragh, MS, Michael Forsyth, RPh, MBA, Roy Beveridge, MD, Carolina Reyes, PhD
Journal: Blood
Blood (2010) 116 (21): 1522.
https://doi.org/10.1182/blood.V116.21.1522.1522
Published: 2010
Journal Articles

Results of a Phase II Open-Label Trial of Bortezomib in Patients with Multiple Myeloma Who Have Undergone High-Dose Melphalan Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation and Failed to Achieve a Complete Response

Robert M. Rifkin, MD, Gary Spitzer, MD, Andrew Greenspan, MD, John F. Schwerkoske, MD, Romeo A. Mandanas, MD, FACP, Joe Stephenson, MD, George T. Kannarkat, Feng Zhan, PhD, Lina Asmar, PhD, Roy Beveridge, MD
Journal: Blood
Blood (2008) 112 (11): 2780.
https://doi.org/10.1182/blood.V112.11.2780.2780
Published: 2008
Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD
Journal: Blood
Blood (2007) 110 (11): 4936.
https://doi.org/10.1182/blood.V110.11.4936.4936
Published: 2007
Journal Articles

Time Burden of Blood Transfusion.

Winston Ueno, MD, Roy Beveridge, MD
Journal: Blood
Blood (2005) 106 (11): 3125.
https://doi.org/10.1182/blood.V106.11.3125.3125
Published: 2005